CISTOSCOPIA VIRTUAL EN EL DIAGNÓSTICO Y SEGUIMIENTO DEL CÁNCER DE VEJIGA

Autores/as

  • David Ibáñez Muñoz
  • Ignacio Quintana Martínez
  • Ana Fernández Militino
  • Daniel Sánchez Zalabardo
  • Rosa Cozcolluela Cabrejas

Palabras clave:

CISTOSCOPIA VIRTUAL, poster, seram, CÁNCER DE VEJIGA, CV

Resumen

Objetivos
OBJETIVO FUNDAMENTAL :
Evaluar la utilidad de la cistoscopia virtual junto a la urografía por TC (URO-TC) en el diagnóstico y seguimiento de los pacientes con carcinoma de vejiga exofítico y plano, y describir la técnica.

Material y métodos
•Pacientes que acudieron a la consulta del Servicio de Urología del Hospital Reina Sofía, derivados de Atención Primaria o del Servicio de Urgencias, y que presentaban hematuria macroscópica. También se efectuó la exploración a uno de cada tres de los pacientes que acudieron a consulta de Urología para
revisión por antecedente de carcinoma vesical ya tratado. 

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Avritscher EB, Cooksley CD, Grossman HB, Sabichi AL, Hamblin L, Dinney CP, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology. 2006;68(3):549-53.

Svatek RS, Hollenbeck BK, Holmang S, Lee R, Kim SP, Stenzl A, et al. The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease. Eur Urol. 2014.

Eble JN, Organización Mundial de la Salud, Organización Internacional para la Investigación del Cáncer. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon Oxford: IARC Press ; Oxford University Press (distributor); 2004. 359 p. p.

Chou R, Dana T. Screening adults for bladder cancer: a review of the evidence for the U.S. preventive services task force. Ann Intern Med. 2010;153(7):461-8.

Mostofi FK, Davis CJ, Sesterhenn I. Histological typing of urinary bladder tumours. 2nd ed. New York ; Berlin: Springer; 1999. xii, 103 p. p.

Epstein JI. The new World Health Organization/International Society of Urological Pathology (WHO/ISUP) classification for TA, T1 bladder tumors: is it an improvement? Crit Rev Oncol Hematol. 2003;47(2):83-9.

Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ, Epstein JI. Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int. 2010;60(1):1-8.

Nishiyama N, Kitamura H, Maeda T, Takahashi S, Masumori N, Hasegawa T, et al. Clinicopathological analysis of patients with non-muscle-invasive bladder cancer: prognostic value and clinical reliability of the 2004 WHO classification system. Jpn J Clin Oncol. 2013;43(11):1124-31.

Dahm P, Gschwend JE. Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur Urol. 2003;44(6):672-81.

Konety BR, Joyce GF, Wise M. Bladder and upper tract urothelial cancer. J Urol. 2007;177(5):1636-45.

Bates AW, Baithun SI. Secondary neoplasms of the bladder are histological mimics of nontransitional cell primary tumours: clinicopathological and histological features of 282 cases. Histopathology. 2000;36(1):32-40.

Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer Available from: http://globocan.iarc.fr, accessed on 09/06/20142013.

Society AC. Cancer Facts and Figures 2014. American Cancer Society, Atlanta. 2014.

Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009;27(3):295-300.

Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64(4):639-53.

Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65(4):778-92.

Bosetti C, Bertuccio P, Chatenoud L, Negri E, La Vecchia C, Levi F. Trends in mortality from urologic cancers in Europe, 1970-2008. Eur Urol. 2011;60(1):1-15.

Mistry M, Parkin DM, Ahmad AS, Sasieni P. Cancer incidence in the United Kingdom: projections to the year 2030. Br J Cancer. 2011;105(11):1795-803.

Fajkovic H, Halpern JA, Cha EK, Bahadori A, Chromecki TF, Karakiewicz PI, et al. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol. 2011;29(4):457-63.

Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234-41.

Yee DS, Ishill NM, Lowrance WT, Herr HW, Elkin EB. Ethnic differences in bladder cancer survival. Urology. 2011;78(3):544-9.

Datta GD, Neville BA, Kawachi I, Datta NS, Earle CC. Marital status and survival following bladder cancer. J Epidemiol Community Health. 2009;63(10):807-13.

Koroukian SM, Bakaki PM, Raghavan D. Survival disparities by Medicaid status: an analysis of 8 cancers. Cancer. 2012;118(17):4271-9.

Zlotta AR, Roumeguere T, Kuk C, Alkhateeb S, Rorive S, Lemy A, et al. Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer. Eur Urol. 2011;59(6):1026-31.

Guey LT, Garcia-Closas M, Murta-Nascimento C, Lloreta J, Palencia L, Kogevinas M, et al. Genetic susceptibility to distinct bladder cancer subphenotypes. Eur Urol. 2010;57(2):283-92. 26. Kiemeney LA, Sulem P, Besenbacher S, Vermeulen SH, Sigurdsson A, Thorleifsson G, et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet. 2010;42(5):415-9.

Kiemeney LA, Thorlacius S, Sulem P, Geller F, Aben KK, Stacey SN, et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet. 2008;40(11):1307-12.

Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet. 2010;42(11):978-84.

Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306(7):737-45.

Zeegers MP, Kellen E, Buntinx F, van den Brandt PA. The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol. 2004;21(6):392-401.

Shapiro JA, Jacobs EJ, Thun MJ. Cigar smoking in men and risk of death from tobacco-related cancers. J Natl Cancer Inst. 2000;92(4):333-7.

Samanic C, Kogevinas M, Dosemeci M, Malats N, Real FX, Garcia-Closas M, et al. Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. Cancer Epidemiol Biomarkers Prev. 2006;15(7):1348-54.

Case RA, Hosker ME. Tumour of the urinary bladder as an occupational disease in the rubber industry in England and Wales. Br J Prev Soc Med. 1954;8(2):39-50.

Rushton L, Hutchings SJ, Fortunato L, Young C, Evans GS, Brown T, et al. Occupational cancer burden in Great Britain. Br J Cancer. 2012;107 Suppl 1:S3-7.

Fernandez MI, Lopez JF, Vivaldi B, Coz F. Long-term impact of arsenic in drinking water on bladder cancer health care and mortality rates 20 years after end of exposure. J Urol. 2012;187(3):856-61.

Letasiova S, Medve'ova A, Sovcikova A, Dusinska M, Volkovova K, Mosoiu C, et al. Bladder cancer, a review of the environmental risk factors. Environ Health. 2012;11 Suppl 1:S11.

Navarro Silvera SA, Rohan TE. Trace elements and cancer risk: a review of the epidemiologic evidence. Cancer Causes Control. 2007;18(1):7-27.

Anetor JI, Wanibuchi H, Fukushima S. Arsenic exposure and its health effects and risk of cancer in developing countries: micronutrients as host defence. Asian Pac J Cancer Prev. 2007;8(1):13-23.

Villanueva CM, Cantor KP, King WD, Jaakkola JJ, Cordier S, Lynch CF, et al. Total and specific fluid consumption as determinants of bladder cancer risk. Int J Cancer. 2006;118(8):2040-7.

Ros MM, Bas Bueno-de-Mesquita HB, Buchner FL, Aben KK, Kampman E, Egevad L, et al. Fluid intake and the risk of urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2011;128(11):2695-708.

Abern MR, Dude AM, Tsivian M, Coogan CL. The characteristics of bladder cancer after radiotherapy for prostate cancer. Urol Oncol. 2013;31(8):1628-34.

He S, Tang YH, Zhao G, Yang X, Wang D, Zhang Y. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. Tumour Biol. 2014;35(3):2095-102.

Messing EM, Vaillancourt A. Hematuria screening for bladder cancer. J Occup Med. 1990;32(9):838-45.

Bhatt J, Cowan N, Protheroe A, Crew J. Recent advances in urinary bladder cancer detection. Expert Rev Anticancer Ther. 2012;12(7):929-39.

Haleblian GE, Skinner EC, Dickinson MG, Lieskovsky G, Boyd SD, Skinner DG. Hydronephrosis as a prognostic indicator in bladder cancer patients. J Urol. 1998;160(6 Pt 1):2011-4.

Nargund VH, Tanabalan CK, Kabir MN. Management of non-muscle-invasive (superficial) bladder cancer. Semin Oncol. 2012;39(5):559-72.

Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol. 2011;186(6):2158-67.

Herr HW, Donat SM, Reuter VE. Management of low grade papillary bladder tumors. J Urol. 2007;178(4 Pt 1):1201-5; discussion 5.

Sylvester RJ, van der Meijden A, Witjes JA, Jakse G, Nonomura N, Cheng C, et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology. 2005;66(6 Suppl 1):90-107.

Rodriguez Faba O, Gaya JM, Lopez JM, Capell M, De Gracia-Nieto AE, Gomez Correa E, et al. Current management of non-muscle-invasive bladder cancer. Minerva Med. 2013;104(3):273-86.

Palou J, Sylvester RJ, Faba OR, Parada R, Pena JA, Algaba F, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin. Eur Urol. 2012;62(1):118-25.

Malmstrom PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247-56.

Han RF, Pan JG. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67(6):1216-23.

Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol. 2006;24(3):296-304.

Nishimura K, Fujiyama C, Nakashima K, Satoh Y, Tokuda Y, Uozumi J. The effects of neoadjuvant chemotherapy and chemo-radiation therapy on MRI staging in invasive bladder cancer: comparative study based on the pathological examination of whole layer bladder wall. Int Urol Nephrol. 2009;41(4):869-75.

Advanced Bladder Cancer Meta-analysis C. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48(2):202-5; discussion 5-6.

Chang SS, Hassan JM, Cookson MS, Wells N, Smith JA, Jr. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol. 2003;170(4 Pt 1):1085-7.

Sanchez-Ortiz RF, Huang WC, Mick R, Van Arsdalen KN, Wein AJ, Malkowicz SB. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol. 2003;169(1):110-5; discussion 5.

Ok JH, Meyers FJ, Evans CP. Medical and surgical palliative care of patients with urological malignancies. J Urol. 2005;174(4 Pt 1):1177-82.

Grossfeld GD, Litwin MS, Wolf JS, Jr., Hricak H, Shuler CL, Agerter DC, et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up. Urology. 2001;57(4):604-10.

Musquera M, Mengual L, Ribal MJ. [Non-invasive diagnosis bladder cancer: new molecular markers and future perspectives]. Arch Esp Urol. 2013;66(5):487-94.

Knox MK, Cowan NC, Rivers-Bowerman MD, Turney BW. Evaluation of multidetector computed tomography urography and ultrasonography for diagnosing bladder cancer. Clin Radiol. 2008;63(12):1317-25.

Clayman RV, Reddy P, Lange PH. Flexible fiberoptic and rigid-rod lens endoscopy of the lower urinary tract: a prospective controlled comparison. J Urol. 1984;131(4):715-6.

Burke DM, Shackley DC, O'Reilly PH. The community-based morbidity of flexible cystoscopy. BJU Int. 2002;89(4):347-9.

Johnson MI, Merrilees D, Robson WA, Lennon T, Masters J, Orr KE, et al. Oral ciprofloxacin or trimethoprim reduces bacteriuria after flexible cystoscopy. BJU Int. 2007;100(4):826-9.

Blick CG, Nazir SA, Mallett S, Turney BW, Onwu NN, Roberts IS, et al. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. BJU Int. 2012;110(1):84-94.

Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-5; discussion 75-7.

Mariappan P, Zachou A, Grigor KM, Edinburgh Uro-Oncology G. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol. 2010;57(5):843-9.

Lawrentschuk N, Lee ST, Scott AM. Current role of PET, CT, MR for invasive bladder cancer. Curr Urol Rep. 2013;14(2):84-9.

Rajesh A, Sokhi HK, Fung R, Mulcahy KA, Bankart MJ. Bladder cancer: evaluation of staging accuracy using dynamic MRI. Clin Radiol. 2011;66(12):1140-5.

Yoshida S, Koga F, Kobayashi S, Ishii C, Tanaka H, Tanaka H, et al. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):e21-7.

Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle. BJU Int. 2013;112(6):729-34.

Bouchelouche K, Choyke PL. PET/Computed Tomography in Renal, Bladder, and Testicular Cancer. PET Clin. 2015;10(3):361-74.

Wang N, Jiang P, Lu Y. Is fluorine-18 fluorodeoxyglucose positron emission tomography useful for detecting bladder lesions? A meta-analysis of the literature. Urol Int. 2014;92(2):143-9.

Lu YY, Chen JH, Liang JA, Wang HY, Lin CC, Lin WY, et al. Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol. 2012;81(9):2411-6.

Apolo AB, Riches J, Schoder H, Akin O, Trout A, Milowsky MI, et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol. 2010;28(25):3973-8.

Cormack AM. Reconstruction of densities from their projections, with applications in radiological physics. Phys Med Biol. 1973;18(2):195-207.

Cormack AM. Representation of a function by its line integrals, with some radiological applications. J Appl Phys. 1963;34:2722.

Schaller S, Flohr T. Computed Tomography — Past, Present and Future. In: Claussen CD, Fishman E, Marincek B, Reiser M, editors. Multislice CT: Springer Berlin Heidelberg; 2004. p. 3-17.

Hounsfield GN. Computerized transverse axial scanning (tomography): Part I. Description of system. 1973. Br J Radiol. 1995;68(815):H166-72.

Bae KW, BR. Basic principles of computed tomography physics and technological considerations. In: Lee JS, SS; Stanley, RJ; Heiken, JP, editor. Computed body tomography with MRI correlation. Filadelfia: Lippincott Williams and Wilkins; 2006. p. 1-28

Kalender WA, Seissler W, Klotz E, Vock P. Spiral volumetric CT with single-breath-hold technique, continuous transport, and continuous scanner rotation. Radiology. 1990;176(1):181-3.

Flohr TG, Schaller S, Stierstorfer K, Bruder H, Ohnesorge BM, Schoepf UJ. Multi-detector row CT systems and image-reconstruction techniques. Radiology. 2005;235(3):756-73.

Cody DD. AAPM/RSNA physics tutorial for residents: topics in CT. Image processing in CT. Radiographics. 2002;22(5):1255-68.

Geenen RW, Hussain SM, Cademartiri F, Poley JW, Siersema PD, Krestin GP. CT and MR colonography: scanning techniques, postprocessing, and emphasis on polyp detection. Radiographics. 2004;24(1):e18.

Rubin GD, Beaulieu CF, Argiro V, Ringl H, Norbash AM, Feller JF, et al. Perspective volume rendering of CT and MR images: applications for endoscopic imaging. Radiology. 1996;199(2):321-30.

Seidelmann FE, Cohen WN, Bryan PJ, Temes SP, Kraus D, Schoenrock G. Accuracy of CT staging of bladder neoplasms using the gas-filled method: report of 21 patients with surgical confirmation. AJR Am J Roentgenol. 1978;130(4):735-9.

Vining DJ, Zagoria RJ, Liu K, Stelts D. CT cystoscopy: an innovation in bladder imaging. AJR Am J Roentgenol. 1996;166(2):409-10.

Tsampoulas C, Tsili AC, Giannakis D, Alamanos Y, Sofikitis N, Efremidis SC. 16-MDCT cystoscopy in the evaluation of neoplasms of the urinary bladder. AJR Am J Roentgenol. 2008;190(3):729-35.

Basak M, Ozkurt H, Tanriverdi O, Cay E, Aydin M, Miroglu C. Sixteen-slice multidetector computed tomographic virtual cystoscopy in the evaluation of a patient with suspected bladder tumor and history of bladder carcinoma operation. J Comput Assist Tomogr. 2009;33(6):867-71.

Panebianco V, Sciarra A, Di Martino M, Bernardo S, Vergari V, Gentilucci A, et al. Bladder carcinoma: MDCT cystography and virtual cystoscopy. Abdom Imaging. 2010;35(3):257-64.

Koplay M, Kantarci M, Guven F, Aksoy Y, Taser F, Ziypak T, et al. Diagnostic efficiency of multidetector computed tomography with multiplanar reformatted imaging and virtual cystoscopy in the assessment of bladder tumors after transurethral resection. J Comput Assist Tomogr. 2010;34(1):121-6.

Qu X, Huang X, Wu L, Huang G, Ping X, Yan W. Comparison of virtual cystoscopy and ultrasonography for bladder cancer detection: a meta-analysis. Eur J Radiol. 2011;80(2):188-97.

Zlotta AR. What is the future of virtual cystoscopy in urology? Can Urol Assoc J. 2011;5(1):38-9.

Amin MF, Abd El Hamid AM. The diagnostic accuracy of multidetector computed tomography with multiplanar reformatted imaging and virtual cystoscopy in the early detection and evaluation of bladder carcinoma: comparison with conventional cystoscopy. Abdom Imaging. 2013;38(1):184-92.

Denholm SW, Conn IG, Newsam JE, Chisholm GD. Morbidity following cystoscopy: comparison of flexible and rigid techniques. Br J Urol. 1990;66(2):152-4.

Karabacak OR, Cakmakci E, Ozturk U, Demirel F, Dilli A, Hekimoglu B, et al. Virtual cystoscopy: the evaluation of bladder lesions with computed tomographic virtual cystoscopy. Can Urol Assoc J. 2011;5(1):34-7.

Sassi C, Santilli L, Concetti S, Schiavina R, Amadori E, Severini E, et al. Three-dimensional computed tomography of the orthotopic ileal neobladder reconstruction: normal and abnormal findings. Urol Int. 2009;82(3):301-5.

Frank R, Stenzl A, Frede T, Eder R, Recheis W, Knapp R, et al. Three-dimensional computed tomography of the reconstructed lower urinary tract: technique and findings. Eur Radiol. 1998;8(4):657-63.

Narumi Y, Kumatani T, Sawai Y, Kuriyama K, Kuroda C, Takahashi S, et al. The bladder and bladder tumors: imaging with three-dimensional display of helical CT data. AJR Am J Roentgenol. 1996;167(5):1134-5.

Song JH, Francis IR, Platt JF, Cohan RH, Mohsin J, Kielb SJ, et al. Bladder tumor detection at virtual cystoscopy. Radiology. 2001;218(1):95-100.

Jinzaki M, Tanimoto A, Shinmoto H, Horiguchi Y, Sato K, Kuribayashi S, et al. Detection of bladder tumors with dynamic contrast-enhanced MDCT. AJR Am J Roentgenol. 2007;188(4):913-8.

Ugarte MD, Militino AF, Arnholt AT. Probability and Statistics with R: CRC Press; 2008.

Fenlon HM, Bell TV, Ahari HK, Hussain S. Virtual cystoscopy: early clinical experience. Radiology. 1997;205(1):272-5.

Tsili A, Tsampoulas C, Chatziparaskevas N, Silakos A, Kalef-Ezra J, Sofikitis N, et al. Computed tomographic virtual cystoscopy for the detection of urinary bladder neoplasms. Eur Urol. 2004;46(5):579-85.

Merkle EM, Fleiter T, Wunderlich A, Rilinger N, Gorich J, Sokiranski R. [Virtual cystoscopy based on spiral CT data]. Rofo. 1996;165(6):582-5.

Arslan H, Ceylan K, Harman M, Yilmaz Y, Temizoz O, Can S. Virtual computed tomography cystoscopy in bladder pathologies. Int Braz J Urol. 2006;32(2):147-54; discussion 54.

Kim JK, Ahn JH, Park T, Ahn HJ, Kim CS, Cho KS. Virtual cystoscopy of the contrast material-filled bladder in patients with gross hematuria. AJR Am J Roentgenol. 2002;179(3):763-8.

Kalokairinou K, Ploumidis A, Kalogeropoulos T, Vlachos L, Stringaris K, Tavernaraki A, et al. The Role of Virtual Cystoscopy, after Multidetector Computed Tomography Imaging Reconstruction without the Use of Contrast Medium, in the Diagnosis and Evaluations of Bladder Tumors: Preliminary Study. Adv Urol. 2014;2014:923958.

Nambirajan T, Sohaib SA, Muller-Pollard C, Reznek R, Chinegwundoh FI. Virtual cystoscopy from computed tomography: a pilot study. BJU Int. 2004;94(6):828-31.

Kim JK, Park SY, Kim HS, Kim SH, Cho KS. Comparison of virtual cystoscopy, multiplanar reformation, and source CT images with contrast material-filled bladder for detecting lesions. AJR Am J Roentgenol. 2005;185(3):689-96.

Gonzalo Rodríguez V, Sanz Justo L, Miguel Santamaría ID, Martínez de Iturrate J, Fernández del Busto E. Empleo del NMP22 Bladder-Chek en el diagnóstico y seguimiento del cáncer de vejiga. Archivos Españoles de Urología (Ed impresa). 2008;61(3):377-84.

Ye Z, Hu J, Song X, Li F, Zhao X, Chen S, et al. A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: A prospective, randomized and multi-center study. Sci Rep. 2015;5:10905.

Herr HW. Narrow Band Imaging for Urothelial Cancer. En Liao JC, Su L-M. Advances in Image-Guided Urologic Surgery: Springer; 2015.p. 11-16

Liu W, Mortele KJ, Silverman SG. Incidental extraurinary findings at MDCT urography in patients with hematuria: prevalence and impact on imaging costs. AJR Am J Roentgenol. 2005;185(4):1051-6.

Cowan NC. CT urography for hematuria. Nat Rev Urol. 2012;9(4):218-26.

Commission. IE. International standard of IEC 60601-2-44 Ed2 Amendment 1: medical electrical equipment, Part 2-44—particular requirements for the safety of x-ray equipment for computed tomography. 2003.

Huda W, Ogden KM, Khorasani MR. Converting dose-length product to effective dose at CT. Radiology. 2008;248(3):995-1003.

Xiao D, Zhang G, Liu Y, Yang Z, Zhang X, Li L, et al. 3D detection and extraction of bladder tumors via MR virtual cystoscopy. Int J Comput Assist Radiol Surg. 2015.

Descargas

Publicado

2018-11-22

Cómo citar

Ibáñez Muñoz, D., Quintana Martínez, I., Fernández Militino, A., Sánchez Zalabardo, D., & Cozcolluela Cabrejas, R. (2018). CISTOSCOPIA VIRTUAL EN EL DIAGNÓSTICO Y SEGUIMIENTO DEL CÁNCER DE VEJIGA. Seram. Recuperado a partir de https://piper.espacio-seram.com/index.php/seram/article/view/1190

Número

Sección

Abdominal

Artículos más leídos del mismo autor/a

1 2 > >>